 |
| Intelligent anti-aging skin care based on independent research |
| Lose wrinkles, keep your bank account! |
|
|
|
|
 |
You are here: Skin Care Research >
Author: Kim EJ; Ramirez AL; Reeck JB; Maas CS
Author affiliation: Division of Facial Plastic and Reconstructive Surgery, University of California, San Francisco, 94115, USA.
Publication date & source: 2003.10, Plast Reconstr Sur, 112(5 Suppl):88S-93S; discussion 94S-97S
Botulinum toxin type B was studied for the management of hyperkinetic facial lines. It showed clinical longevity of up to 12 weeks on subjective rating scales and 8 weeks on objective rating scales. Botulinum toxin type B has shown relative safety but can have autonomic side effects at higher total doses, which limits the possibility of continued dose escalation. Although these findings may preclude its use as a primary modality for the use in hyperkinetic facial lines, botulinum toxin type B still has a role in the treatment of the aesthetic patient and is yet another tool in the armamentarium of aesthetic practitioners.
Home | About Us | Contact Us | Ask a Question | Resources Copyright © 1999-2009 by Dr. G. Todorov / SmartSkinCare.com Site Disclaimer | Copyright Certification
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||